166 related articles for article (PubMed ID: 27163775)
1. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.
Hambuchen MD; Rüedi-Bettschen D; Gunnell MG; Hendrickson H; Owens SM
Hum Vaccin Immunother; 2016 Sep; 12(9):2240-8. PubMed ID: 27163775
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.
White SJ; Hendrickson HP; Atchley WT; Laurenzana EM; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2014 Aug; 42(8):1285-91. PubMed ID: 24839971
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
7. The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.
Harris AC; LeSage MG; Shelley D; Perry JL; Pentel PR; Owens SM
PLoS One; 2015; 10(3):e0118787. PubMed ID: 25742165
[TBL] [Abstract][Full Text] [Related]
8. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.
Laurenzana EM; Byrnes-Blake KA; Milesi-Hallé A; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2003 Nov; 31(11):1320-6. PubMed ID: 14570763
[TBL] [Abstract][Full Text] [Related]
9. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat.
Rivière GJ; Byrnes KA; Gentry WB; Owens SM
J Pharmacol Exp Ther; 1999 Dec; 291(3):1220-6. PubMed ID: 10565845
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment with curcumin enhances methamphetamine locomotor sensitization and cue-induced reinstatement of methamphetamine self-administration.
Zhao C; Lou Z; Zimmer B; Yu Z; Li P; Ma B; Sun Y; Huang K; Zhou W; Liu Y
Pharmacol Biochem Behav; 2012 Oct; 102(4):555-61. PubMed ID: 22750063
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of an exaggerated locomotor response to a low-dose challenge of methamphetamine.
Frankel PS; Hoonakker AJ; Danaceau JP; Hanson GR
Pharmacol Biochem Behav; 2007 Mar; 86(3):511-5. PubMed ID: 17303233
[TBL] [Abstract][Full Text] [Related]
13. Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats.
Laurenzana EM; Hendrickson HP; Carpenter D; Peterson EC; Gentry WB; West M; Che Y; Carroll FI; Owens SM
Vaccine; 2009 Nov; 27(50):7011-20. PubMed ID: 19800446
[TBL] [Abstract][Full Text] [Related]
14. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
[TBL] [Abstract][Full Text] [Related]
15. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.
Hambuchen MD; Carroll FI; Rüedi-Bettschen D; Hendrickson HP; Hennings LJ; Blough BE; Brieaddy LE; Pidaparthi RR; Owens SM
J Med Chem; 2015 Jun; 58(11):4665-77. PubMed ID: 25973614
[TBL] [Abstract][Full Text] [Related]
16. Berberine hydrochloride attenuates voluntary methamphetamine consumption and anxiety-like behaviors via modulation of oxytocin receptors in methamphetamine addicted rats.
Alavijeh MM; Vaezi G; Khaksari M; Hojati V
Physiol Behav; 2019 Jul; 206():157-165. PubMed ID: 30922821
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.
Ruda-Kucerova J; Babinska Z; Stark T; Micale V
Neurotox Res; 2017 Jul; 32(1):121-133. PubMed ID: 28421529
[TBL] [Abstract][Full Text] [Related]
18. A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior.
Hall DA; Stanis JJ; Marquez Avila H; Gulley JM
Psychopharmacology (Berl); 2008 Jan; 195(4):469-78. PubMed ID: 17874316
[TBL] [Abstract][Full Text] [Related]
19. Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine.
Ito K; Abekawa T; Koyama T
Psychopharmacology (Berl); 2006 Jul; 186(4):525-33. PubMed ID: 16758239
[TBL] [Abstract][Full Text] [Related]
20. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.
Rüedi-Bettschen D; Wood SL; Gunnell MG; West CM; Pidaparthi RR; Carroll FI; Blough BE; Owens SM
Vaccine; 2013 Sep; 31(41):4596-602. PubMed ID: 23906885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
